GSK, Targacept ink $1.5B pain deal
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
GSK |
Targacept |
$1.5B deal |
GSK and Targacept have inked a discovery, development and commercialization deal for therapeutics that target specified neuronal nicotinic receptors. |
|
Meda |
MedPointe |
$800M buyout |
Meda said that MedPointe's products, which focus on the areas of allergy, respiratory and pain, are a perfect fit for Meda's portfolio. |
|
Genstar Capital |
PRA International |
$744 buyout |
Genstar Capital has struck a deal to buy PRA International for $744 million, a premium of about 13 percent on PRA's stock price. PRA gets 50 days to solicit a better offer. |
|
Merck |
NovaCardia |
$350M buyout |
NovaCardia has a drug--KW-3902--in late-stage studies for congestive heart failure. |
|
Pfizer Global R&D |
Hydra Biosciences |
$195M deal |
Hydra stands to gain up to $195 million in up front and milestone payments the first product developed from the Transient Receptor Potential channel family. |
|
SurModics |
Brookwood Pharmaceuticals |
$62M sale |
The Southern Research Institute has sold Brookwood Pharmaceuticals to SurModics for $40M up front and up to $22M in milestones. Both SurModics and Brookwood specialize in drug delivery technologies. |
|
Cell Therapeutics |
Systems Medicine |
$35M buyout |
Systems Medicine is developing a genetically engineered drug called Brostallicin, which Cell Therapeutics believes is a "perfect fit" for its pipeline. |
|
Antares Pharma |
Jazz Pharmaceuticals |
$16.5M development and licensing deal |
The deal is for the development of therapeutics for an unnamed CNS disorder based on Antares' Advanced Transdermal Delivery system. |